LLY

1,064.11

+2.13%↑

JNJ

234.43

+1.74%↑

ABBV

216.94

+0.77%↑

UNH

388.84

+1.3%↑

AZN

188.07

-0.94%↓

LLY

1,064.11

+2.13%↑

JNJ

234.43

+1.74%↑

ABBV

216.94

+0.77%↑

UNH

388.84

+1.3%↑

AZN

188.07

-0.94%↓

LLY

1,064.11

+2.13%↑

JNJ

234.43

+1.74%↑

ABBV

216.94

+0.77%↑

UNH

388.84

+1.3%↑

AZN

188.07

-0.94%↓

LLY

1,064.11

+2.13%↑

JNJ

234.43

+1.74%↑

ABBV

216.94

+0.77%↑

UNH

388.84

+1.3%↑

AZN

188.07

-0.94%↓

LLY

1,064.11

+2.13%↑

JNJ

234.43

+1.74%↑

ABBV

216.94

+0.77%↑

UNH

388.84

+1.3%↑

AZN

188.07

-0.94%↓

Home・Lista de Ações・Kura Oncology Inc

Kura Oncology Inc

Abrir

SetorSaúde

11.39 0.18

Comprar Vender

Visão Geral

Variação de preço das ações

24h

Atual

Mín

10.97

Máximo

11.5

Indicadores-chave
By Trading Economics
Rendimento	7.7M -73M
Vendas	929K 18M
Margem de lucro	-401.495
Funcionários	260
EBITDA	7.4M -78M

Recomendações
By TipRanks
Recomendações	Compra Forte
Previsão para 12 meses	+172.05% upside

Dividendos
By Dow Jones
Próximos Ganhos	6 de ago. de 2026

Estatísticas de Mercado
By TradingEconomics
Capitalização de Mercado	-31M 813M
Abertura anterior	11.21
Fecho anterior	11.39

Sentimento de Notícias

By Acuity

100%

327 / 345 Ranking em Healthcare

Pontuação Técnica

By Trading Central

Confiança

Very Strong Bearish Evidence

5.575 / 6.6 Suporte e Resistência

Kura Oncology Inc Gráfico

O desempenho passado não é um indicador confiável de resultados futuros.

Notícias Relacionadas

21 de mai. de 2026, 22:48 UTC

Aquisições, Fusões, Aquisições de Empresas

Conduent to Sell Public Transit Business to Modaxo for $164 Million

21 de mai. de 2026, 16:49 UTC

Ganhos

Walmart's Fuel Business Benefits from Rising U.S. Gas Prices, Though Volume Per Transaction Falls -- OPIS

21 de mai. de 2026, 16:26 UTC

Grandes Movimentos do Mercado

Spotify Technology Shares Up Amid New AI Tool For Remixing Songs

21 de mai. de 2026, 23:51 UTC

Conversa de Mercado

Nikkei Might Rise on Continued Hopes for Possible U.S.-Iran Deal -- Market Talk

21 de mai. de 2026, 23:37 UTC

Ganhos

Lenovo Group 4Q Oper Profit $886.0M Vs. $331.0M >0992.HK

21 de mai. de 2026, 23:37 UTC

Ganhos

Lenovo Group 4Q Rev $21.60B Vs. $16.98B >0992.HK

21 de mai. de 2026, 23:37 UTC

Ganhos

Lenovo Group 4Q Net $521.0M Vs. Net $90.0M >0992.HK

21 de mai. de 2026, 23:34 UTC

Conversa de Mercado

Gold Edges Lower Amid Mixed Sentiment -- Market Talk

21 de mai. de 2026, 23:30 UTC

Conversa de Mercado

Global Equities Roundup: Market Talk

21 de mai. de 2026, 23:30 UTC

Conversa de Mercado

Napier Port Loses Bull Despite Robust 1H Result -- Market Talk

21 de mai. de 2026, 22:33 UTC

Aquisições, Fusões, Aquisições de Empresas

Conduent to Sell Public Transit Business to Modaxo for $164M

21 de mai. de 2026, 21:53 UTC

Ganhos

Marvell Stock Notches Its 15th Record Closing High This Year -- Barrons.com

21 de mai. de 2026, 21:02 UTC

Ganhos

These Stocks Are Today's Movers: Nvidia, IBM, Rigetti, Nebius, Bloom Energy, Applied Digital, Intuit, D-Wave, Spotify, and More -- Barrons.com

21 de mai. de 2026, 20:55 UTC

Ganhos

Walmart Sales Rise as It Navigates Higher Fuel Prices -- 2nd Update

21 de mai. de 2026, 20:30 UTC

Ações em Alta

Stocks to Watch Recap: Nvidia, Spotify, Stellantis, Intuit -- WSJ

21 de mai. de 2026, 20:20 UTC

Conversa de Mercado

Global Forex and Fixed Income Roundup: Market Talk

21 de mai. de 2026, 20:20 UTC

Conversa de Mercado

Mexico's Revised 1Q GDP Seen Confirming Contraction -- Market Talk

21 de mai. de 2026, 20:20 UTC

Ganhos

Webull 1Q Adj EPS 3c >BULL

21 de mai. de 2026, 20:20 UTC

Ganhos

Webull 1Q Rev $159.9M >BULL

21 de mai. de 2026, 20:18 UTC

Conversa de Mercado

Mexico's Inflation Seen Easing in Early May -- Market Talk

21 de mai. de 2026, 20:18 UTC

Ganhos

Webull 1Q Loss/Shr 4c

21 de mai. de 2026, 19:43 UTC

Conversa de Mercado

Oil Futures Lose Ground on Hopes for U.S.-Iran Deal -- Market Talk

21 de mai. de 2026, 19:33 UTC

Conversa de Mercado

U.S. Natural Gas Futures Edge Up in Steady Trading -- Market Talk

21 de mai. de 2026, 18:58 UTC

Ganhos

Nvidia Is Now the Megacap Cash Machine, and Big Tech Is Footing the Bill -- Barrons.com

21 de mai. de 2026, 18:15 UTC

Conversa de Mercado

Gold Higher For Second Consecutive Day -- Market Talk

21 de mai. de 2026, 17:40 UTC

Conversa de Mercado

Prolonged War Putting Energy Normalcy Further Away -- Market Talk

21 de mai. de 2026, 17:04 UTC

Conversa de Mercado

SpaceX Revealed as Top 10 Bitcoin Holder -- Market Talk

21 de mai. de 2026, 17:01 UTC

Ganhos

These Stocks Are Today's Movers: Nvidia, IBM, Rigetti, GlobalFoundries, Nebius, Applied Digital, Intuit, Spotify, and More -- Barrons.com

21 de mai. de 2026, 16:20 UTC

Conversa de Mercado

Ganhos

Stellantis Targets Distant but Constructive -- Market Talk

21 de mai. de 2026, 16:20 UTC

Conversa de Mercado

Financial Services Roundup: Market Talk

Comparação entre Pares

Variação de preço

Kura Oncology Inc Previsão

Preço-alvo

By TipRanks

172.05% parte superior

Previsão para 12 meses

Média 28.13 USD 172.05%

Máximo 40 USD

Mínimo 15 USD

Com base em 10 analistas de Wall Street que oferecem metas de preço de 12 meses para Kura Oncology Inc - Dist nos últimos 3 meses.

Consenso de Avaliação

By TipRanks

Compra Forte

10 ratings

Comprar

Manter

Vender

Com base em 10 analistas que deram avaliações de ações para Kura Oncology Inc - Dist nos últimos 3 meses.

Pontuação Técnica

By Trading Central

5.575 / 6.6Suporte e Resistência

Recent bearish events outweigh bullish events.

Recent bullish events outweigh bearish events.

All events are bearish.

Sentimento

By Acuity

327 / 345 Ranking em Saúde

Informação Financeira

Custos administrativos e de venda

Custos Operacionais

Lucro antes de imposto

Vendas

Custo das vendas

Lucro bruto sobre vendas

Despesa com juros da dívida

EBITDA

Resultado Operacional

Sobre Kura Oncology Inc

Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company's pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors. It has a clinical collaboration with Novartis Pharma AG to evaluate the combination of tipifarnib and alpelisib in patients with head and neck squamous cell carcinoma whose tumors have HRAS overexpression and/or PIK3CA mutation and/or amplification; and strategic collaboration agreement with Kyowa Kirin Co., Ltd. to develop and commercialize its oral menin inhibitor for the treatment of patients with acute myeloid leukemia (AML) and other hematologic malignancies. The company was founded in 2014 and is headquartered in San Diego, California.